Clinical Laserthermia Systems publishes supplementary prospectus regarding ongoing rights issue
Clinical Laserthermia Systems AB (publ) (“CLS” or the ”Company”) has drafted a supplementary prospectus (the ”Supplementary Prospectus”) to the EU growth prospectus approved and registered by the Swedish Financial Supervisory Authority (SW: Finansinspektionen) on June 10, 2024 (the “Prospectus”). The Supplementary Prospectus has today, June 20, 2024, been approved and registered by the Swedish Financial Supervisory Authority.The Prospectus has been drafted in connection with the ongoing rights issue of units consisting of new B-shares and warrants of series TO 7 B, which was resolved by the